Ankaferd® Kanama Durdurucunun Rat Abdominal Aort Kanama Modelinde Kanama Zamanına Etkisi (original) (raw)
Related papers
DergiPark (Istanbul University), 2016
Introduction: The use of topical haemostatic agents has been popularised in recent years in many areas of surgery. We aimed to determine whether Ankaferd blood stopper ® (ABS) can shorten the bleeding time and decrease the amount of bleeding in a rat abdominal aortic bleeding model. Patients and Methods: A total of 40 rats were randomly divided into four groups (n= 10 in each group). Saline-and ABS-soaked gauzes were applied to rats that had not received any pre-treatment in Groups 1 and 2, while saline-and ABS-soaked gauzes were applied to rats that had received acetylsalicylic acid plus oral clopidrogel for 5 days in Groups 3 and 4. An incision of about 1 mm was made over the aorta just proximal to the iliac bifurcation. Mean bleeding time (MBT) and mean bleeding amount (MBA) were determined and compared. Results: There were no signifi cant differences in the age, weight and blood sample laboratory results of rats. Shorter MBT and less MBA were determined in ABS-soaked groups and the differences were statistically signifi cant. Conclusion: Ankaferd blood stopper ® has the potential to reduce the bleeding time and post-operative blood loss after a major aortic surgery.
Journal of Cardiothoracic Surgery, 2010
Background Ankaferd Blood Stopper® (ABS) is a folkloric medicinal plant extract used as a hemostatic agent in traditional Turkish medicine. This experimental study investigated the histopathological and immunohistochemical effects of ABS on vascular tissue in a rat model of aortic bleeding. Methods Four groups of 11 Wistar albino rats were used. The abdominal aortas of the rats were wounded; an ABS-soaked tampon was applied to rats in Groups 1 and 3, and a plain gauze tampon was applied to rats in Groups 2 and 4 until the bleeding stopped. The bleeding time was recorded. Immediately following sacrificing, the arteriotomy sites from Groups 1 and 2 were removed. The abdominal incisions in Groups 3 and 4 were closed following hemostasis. On Day 7 of the study, Group 3 and 4 rats were sacrificed and the abdominal aorta arteriotomy sites were removed for histopathological and immunohistochemical evaluation. Results The mean bleeding time in 15 animals in Groups 2 and 4 was 4.9 ± 0.6 s, and in 22 animals in Groups 1 and 3 was 3.1 ± 0.6 s. Distal aortic occlusion was not observed on either Day 1 or 7 in any group. Significantly more widespread and dense endothelial nitric oxide synthase (eNOS) staining was observed in Group 1 animals than Group 2. On Days 1 and 7 after application of ABS, histopathological changes, consisting of necrosis, inflammation, and endothelial cell loss, in the rat abdominal aortas did not differ between Groups 1 and 2. The basophilic discoloration in the ABS group on the operation day was a result of a foreign body reaction and hemosiderin-loaded histiocyte accumulation, which occurred on Day 7. Conclusions In this study, hemostasis was successfully achieved with ABS in rat abdominal aortas. No histopathological change was found in the rat abdominal aortas between the ABS and control groups on Days 1 and 7. Further studies on the long-term effects of foreign body reactions and hemosiderin-loaded histiocyte accumulation are required.
Clinical and Applied Thrombosis/Hemostasis, 2013
Purpose: The purpose of this study is to investigate the hispathological, biochemical, and clinical efficiency of Ankaferd Blood Stopper (ABS) in preventing postoperative intraabdominal adhesions. Method: A total of 40 Wistar albino species female rats were randomly separated into 4 groups. For the control group, 1 mL normal saline was administered; and for the second, third, and fourth groups 0.5, 1, and 2 mL, respectively, ABS was administered. Statistical analyses were evaluated with Tukey and analysis of variance test. Findings: Significant increase was observed in fibroblast and vascularization microscopically with increasing amount of ABS used. Degree of adhesion in the group administered with normal saline was lower compared to the other groups. Adhesion thickness and prevalence macroscopically increased with the increasing amount of ABS used in groups. Conclusion: It was determined in our study that ABS is not efficient in preventing intraabdominal adhesions; on the contrary...
Meandros Medical and Dental Journal
Amaç: Ankaferd kanama durdurucu, eksternal hemorajinin tedavisinde hemostatik bir ajan olarak kullanılan beş tıbbi bitki özütünün bir karışımıdır. Bu çalışmanın amacı, Ankaferd kanama durdurucusunun (ABS) antitrombotik ilaç almış in vivo modellerde diş çekimi sonrası kanama üzerine hemostatik etkilerini değerlendirmektir. Öz Objective: Ankaferd blood stopper is a mixture of five medicinal plant extracts used as a hemostatic agent for management of external hemorrhage. The aim of this study was to evaluate the hemostatic effects of Ankaferd blood stopper (ABS) on bleeding after tooth extraction in vivo models with taking antithrombotic drug. Materials and Methods: Forty-eight male Albino Wistar rats were divided into six groups of 8 animals each. Maxillary right first molar tooth of the rats were extracted under general anesthesia. 2 mL saline solutions were applied topically to Control group (group 1), Warfarin group (group 3) and Heparin group (group 5) on the sockets immediately after extraction. Two ml ABS's were applied topically to Ankaferd group (group 2), Warfarin-Ankaferd group (group 4) and Heparin-Ankaferd group (group 6) likewise. The bleeding time and the amount of bleeding were compared among 6 groups just following the tooth extraction. The collected data results were analysed statistically by the ANOVA followed by Tukey test for pair-wise comparisons. Results: The bleeding time was longer in Warfarin and Heparin group than the Control group (p<0.05), Ankaferd, Warfarin-Ankaferd and Heparin-Ankaferd groups (p>0.05). Similiarly, the amount of bleeding of Warfarin group was significantly higher than those of the Control and Warfarin-Ankaferd group (p<0.05). The amount of bleeding were lower in Control, Heparin and Heparin-Ankaferd groups but the differences were not statistically significant (p>0.05). Conclusion: Topically administered ABS is less effective on bleeding control of Warfarin-induced bleeding model than Heparin-induced bleeding model in wistar rats. Resulting small difference in between warfarin and heparin should be investigated in future studies.
Turkish Journal of Hematology, 2011
Objective: The aim of this study was to assess the surgical and histopathological hemostatic effects of topical Ankaferd blood stopper (ABS) on major arterial vessel injury related to elevated intra-arterial blood pressure in an experimental rabbit model. Materials and Methods: The study included 14 New Zealand rabbits. ABS was used to treat femoral artery puncture on 1 side in each animal and the other untreated side served as the control. Likewise, for abdominal aortic puncture, only 50% of the aortic injuries received topical liquid ABS and the others did not (control). The experiment was performed under conditions of normal arterial blood pressure and was repeated with a 50% increase in blood pressure. Histopathological analysis was performed in all of the studied animals. Results: Mean bleeding time in the control femoral arteries was 105.0±18.3 s, versus 51.4±9.8 s (p<0.05) in those treated with ABS. Mean blood loss from the punctured control femoral arteries was 5.0±1.5 mg and 1.6±0.4 mg from those treated with ABS (p<0.05). Histopathological examination of the damaged arterial structures showed that ABS induced red blood cell aggregates. Conclusion: ABS administered to experimental major arterial vessel injury reduced both bleeding time and blood loss under conditions of normal and elevated intra-arterial blood pressure. ABS-induced erythroid aggregation was prominent at the vascular tissue level. These findings will inform the design of future experimental and clinical studies on the anti-bleeding and vascular repairing effects of the novel hemostatic agent ABS. (Turk J Hematol 2011; 28: 206-12)
Evaluation of a New Hemostatic Agent Ankaferd Blood Stopper in Experimental Liver Laceration
Journal of Investigative Surgery, 2009
Introduction: Hemorrhage is a leading cause of death after trauma. It is also the major cause of operating room deaths among patients who undergo liver surgery. Various techniques and materials have been attempted to manage bleeding, but a standard method has not been defined yet. We studied the hemostatic effects of Ankaferd Blood Stopper on liver injury in comparison with regenerated oxidized cellulose. Materials and Methods: Thirty Wistar albino rats underwent partial hepatic laceration by scissors. The animals were randomized to the treatment of resected surface with either Ankaferd Blood Stopper ⃝ R (ABS, n = 11) or regenerated oxidized cellulose (Surgicel ⃝ R , n = 9), or were left untreated (controls, n = 10). All the animals were resuscitated with lactated Ringer's solution at 3.3 ml/min/kg to a mean arterial pressure (MAP) of 100 mmHg. Survival time, total blood loss, resuscitation volume, and MAP were recorded for 30 min or until death. The rats that were alive at the end of 30 min were sacrificed with blood withdrawal from catheters. Results: Rats in the ABS and Surgicel groups survived significantly longer than rats in the control group (p = .0001). There were no significant differences between the ABS and the Surgicel groups in survival (p = .91). Application of ABS and Surgicel was associated with a significant reduction in blood loss compared to controls (p = .008), with no significant differences between active treatment groups (p = .74). The resuscitation volume was not different. Conclusions: ABS is as effective as Surgicel in achieving hemostasis following partial liver excision in an experimental rat model.
Efficacy of Ankaferd Blood Stopper in Bleeding Control in Experimental Partial Splenectomy Model
Kafkas Universitesi Veteriner Fakultesi Dergisi, 2012
Topical hemostatic agents are used as auxiliary agents for bleeding post trauma and during operation. Ankaferd Blood Stopper (ABS) is an hemostatic agent that is produced in Turkey. We planned to demonstrate the efficacy of this agent in experimental splenectomy model and to compare it with Fibrin Glue (Tisseel®) used in clinics. Forty Wistar Albino female rats were divided in 5 groups. Group 1, Sham; Group 2, Control; Group 3, Suture; Group 4, Fibrin Glue (Tisseel®) and Group 5, Ankaferd Blood Stopper. Partial splenectomy bleeding model was applied to rats after initial hematocrit values were measured. Bleeding in each group was controlled by a different method. Bleeding times of the rats were determined. All the rats were sacrificed on the 5th day after the last hematocrit values were measured. Existence of intraabdominal hematoma and adhesiveness were evaluated and splectonomy was applied for pathological examination. Groups were compared with respect to bleeding time and blood loss and Group 5 and Group 2 were determined to be more effective than Group 3 but Group 4 was determined to be equivalent. Fewer side effects at significant levels were detected in terms of fibrosis and coagulation necrosis during pathological assessment. In conclusion, in spleen bleedings when compared with fibrin glue, Ankaferd Blood Stopper is equally effective and safe and its price is lower.
Blood Coagulation & Fibrinolysis, 2009
Ankaferd comprises a standardized mixture of plants Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum and Urtica dioica. Ankaferd Blood Stopper (ABS) as a medicinal product has been approved in the management of external hemorrhage and dental surgery bleedings in Turkey. This study aimed to evaluate the in-vivo hemostatic effect of ABS in rats pretreated with acetylsalicylic acid or enoxaparin. Wistar rats (210-270 g) of both sexes were used in this study. The animals were pretreated with acetylsalicylic acid (10 mg/kg) orally for 4 days or enoxaparin sodium (8 mg/kg) subcutaneously for 3 days or did not receive any anticoagulant before tail cut at 4th day. ABS was administered topically [a total of 4 ml (1 ml/puff T 4)] to the cut tail in the studied animals. The duration of bleeding and the amount of bleeding were measured in order to evaluate the hemostatic effect of ABS. In acetylsalicylic acid-treated animals, topical ABS reduced both the duration and also the amount of bleeding volume by 68.4 and 54.6%, respectively. It was also effective in shortening the duration of bleeding (30.6%) and decreasing the amount of bleeding (32.8%) in enoxaparin-treated animals. ABS, a traditional folkloric medicinal plant extract, has in-vivo hemostatic actions, which may provide a therapeutic potential for the management of patients with deficient hemostasis in the clinical medicine.
Use of Ankaferd Blood Stopper as a hemostatic agent: a clinical experience
The journal of contemporary dental practice
To determine the efficacy of the topical application of Ankaferd Blood Stopper (ABS) on hemorrhagic diathesis following dental procedures under different conditions. Some patients have a tendency to bleed excessively after dental surgery for a variety of reasons, making oral surgical procedures more risky for these patients. Since hemorrhage can cause major morbidity and mortality, the identification of a novel, effective hemostatic agent could improve the management of excessive bleeding that occurs during dental procedures. Four patients (3 females, 1 male) aged 28-45 with bleeding tendencies due to different presurgical conditions such as von Willebrand Disease, chronic liver failure, and mitral valve replacement presented for tooth extraction. Hematological consultations were obtained prior to surgical intervention and their international normalized (INR) ratio values were adjusted to less than 1.5; none received clotting factor replacement. All the extractions were performed un...
Of a Haemostatic Agent in Rabbits
2010
Topical hemostatic agents are applied locally to areas of injured vascular endothelium to control local bleeding. Ankaferd Blood Stopper (ABS) has gained approval in Turkey and Bosnia-Herzegovina as a topical haemostatic agent for external post-surgical and post-dental surgery bleeding. The safety of topical use of ABS has been demonstrated in numerous in vitro and in vivo animal models, as well as in a clinical Phase I trial in humans. ABS, besides its haemostatic activity, also has in vitro anti-infectious and anti-neoplastic effects. To assess potential detrimental effects of intravenous administration of ABS into intact systemic circulation in a rabbit experimental model, one milliliter of ABS was administered intravenously into the systemic circulation of twelve rabbits which were included in the study via the marginal ear vein. Animals were observed for 1 hr before euthanasia was performed by administering 40 mg of intracardiac suxamethonium chloride. In the event of death (ca...